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Abstract 
Background: Pharmaceutical advertising, in a variety of forms, has been shown to influence prescribing behaviour. Regulatory systems have 
therefore been concerned with the quality of advertising and compliance with either imposed or self-regulatory codes of practice. Although the South 
African Medicines Act provides for an enforceable code of practice, the draft version published in 2004 has yet to be put into effect. This study aimed 
to assess the quality of pharmaceutical advertisements for reproductive health products, published in South African medical publications over the 
period 2001 to 2005. Compliance with the draft code of practice was considered, as well as the usefulness of the code itself.
Methods: Half-page and larger print advertisements for reproductive health medicines were sought from two South African peer-reviewed and 
four non-peer-reviewed medical publications. Advertisements published in three consecutive months in 2001 to 2005 were selected. This period 
represented the period prior to legislation being developed and the period during which the code of practice was developed and published for 
comment. Details from each advertisement were captured independently by two reviewers using a pre-determined, pre-tested 60-question 
questionnaire. Differences were resolved by consensus. The questionnaire was pre-tested and adapted before being applied. Questions sought to 
identify characteristics of the advertisement that were indicative of quality relating to claims and evidence used in support of the claims, as well as 
adherence to the draft code of practice. The number of claims made in each advertisement was identified, and for each claim the evidence provided 
in the form of references was assessed. 
Results: A total of 136 reproductive health product advertisements were retrieved from 105 medical publications. Only 63 advertisements were 
unique. On average each medical publication selected contained 1.3 reproductive health product advertisements. All but three advertisements were 
for registered orthodox medicines. A total of 191 ‘claims’ could be discerned in advertisements placed in medical publications (average 3.0 ‘claims’ 
per advertisement). Only 7/103 (6.8%) references cited in unique advertisements in medical publications could be retrieved in abstract form from 
Medline, and only 1/7 (14.3%) of these references could be retrieved in free full-text format. In total, 14/103 (13.6%) of the references cited in 
advertisements placed in medical publications were listed as “data on file”. Compliance with the relevant general regulation was easier to judge, and 
seen more often, than was the case in respect of the more subjective elements included in the draft code of practice.
Conclusions: The quality of advertisements for reproductive health products placed in medical publications appears to fall short of at least some 
of the requirements of both existing and draft regulatory instruments. This may potentially have deleterious consequences for both prescriber and 
consumer behaviour. The draft code of practice is, however, often difficult to apply in an objective and consistent manner, and may be open to 
interpretation and therefore variable standards of quality.
SA Fam Pract 2009;51(1):53-58
Introduction
The potential influence of commercial sources of information on 
medicines, such as printed advertisements, on the prescribing behaviour 
of health professionals has long been a source of concern.1 Control 
over the content and quality of pharmaceutical advertising is therefore 
considered to be a key element of medicines regulatory practice. In 
South Africa, the National Drug Policy, approved by the Cabinet in 
1996, committed to the following stance: “The objective is to ensure 
that advertising and marketing of drugs shall be in keeping with the 
National Drug Policy, and in compliance with national regulations, as well 
as with voluntary industry standards. All promotion-making claims shall 
be reliable, accurate, truthful, informative, balanced, up-to-date, capable 
of substantiation and in good taste. They shall not contain misleading 
or unverifiable statements or omissions likely to induce medically 
unjustifiable drug use or to give rise to undue risks. Promotional material 
shall not be designed to disguise its real nature.”2 This was codified in 
the Medicines Act, Section 18C, which reads as follows: “The Minister 
shall, after consultation with the pharmaceutical industry and other 
stakeholders, make regulations relating to the marketing of medicines, 
and such regulations shall also provide for an enforceable Code of 
Practice.”3 Following the withdrawal of the court action blocking the 
promulgation of the 1997 Amendment Act which introduced this section, 
this envisaged code of practice was co-developed by the pharmaceutical 
industry and representatives of the regulatory authority. It was published 
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as part of a draft set of General Regulations to the Medicines Act in 
May 2004.4 Although comment was invited and received, these regulations 
were never issued in final form. The code of practice therefore remains 
in draft form only and unenforced. General Regulation No. 45, covering 
the advertisement of medicines, was brought into effect in 2003, and 
remains the only extant regulatory instrument in this area.5 
The code of practice, which deals with the marketing of medicines in 
South Africa, is divided into five parts. The five parts deal with marketing 
to health care professionals; marketing to the general public; marketing 
of complementary medicines to healthcare professionals; marketing of 
complementary medicines to the general public; and the authority of the 
code. Part 1A of the code, with particular reference to clauses 1 to 5, 
was relevant to this study in that it dealt with the marketing of medicines 
to healthcare professionals with specific reference to registration; 
prescribing information and other obligatory information; abbreviated 
advertisements; journal advertisements; and information, claims and 
comparisons.
The extent to which the requirements of the code are already adhered 
to, or whether there has been movement towards compliance over time, 
has not been assessed in South Africa. No assessments of the quality of 
print or other forms of advertisements for medicines in South Africa have 
been published. This study aims to assess the quality of pharmaceutical 
advertisements for reproductive health products, published in South 
African medical publications over the period 2001 to 2005. Compliance 
with the draft code of practice was considered, as was the usefulness of 
the code itself. Reproductive health was chosen as an exemplar based 
on the wide range of possible products, the applicability to both male and 
female medical care and the likelihood that new product advertisements 
would appear in the period under review. No single pharmacological 
category has been selected in other studies, making comparison on this 
basis impossible. 
Methods
Half-page and larger print advertisements for reproductive health 
medicines were sought from a range of South African peer-reviewed 
(South African Medical Journal, South African Family Practice) and non-
peer-reviewed (CME, Medical Chronicle, Modern Medicine, Update) 
medical publications. Advertisements published in January, February and 
March of the years 2001 to 2005 were selected. This period represented 
the period prior to legislation being developed (in particular the Medicines 
and Related Substances Control Amendment Act, No. 90 of 1997) and the 
period during which the code of practice was developed and published 
for comment. Where a publication from a particular month could not be 
sourced, the issue from the next available month in the same year was 
used. Advertisements for both complementary and orthodox medicines 
were sought, covering areas such as fertility, contraception, pregnancy, 
menstruation, menopause and sexual dysfunction.
Details from each advertisement were captured independently by two 
reviewers using a pre-determined questionnaire. Both reviewers are 
pharmacists with postgraduate training in pharmacology. One (AS) has 
extensive experience in the marketing of pharmaceutical products, 
while the other (AG) is experienced in the field of drug policy and 
rational medicines use. Differences were resolved by consensus. The 
questionnaire (which is attached) was pre-tested and adapted before 
being applied. The questionnaire comprised 60 questions, of which three 
were specific to consumer publications. Questions sought to identify 
characteristics of the advertisements that were indicative of quality 
relating to claims and evidence used in support of the claims, as well 
as adherence to the draft code of practice. The number of claims made 
in each advertisement was identified, and for each claim the evidence 
provided in the form of references was assessed. References cited were 
searched for in Medline (PubMed) and, if possible, retrieved in free full-
text format. 
Results
A total of 136 reproductive health product advertisements were retrieved 
from 105 medical publications. There was evidence of substantial 
use of the same advertisement across different publications. Only 63 
advertisements from medical publications were unique. On average each 
medical publication selected contained 1.3 reproductive health products. 
The sources of these advertisements over time are shown in Table I. 
All but three advertisements were for registered orthodox medicines. 
All three advertisements for unregistered complementary medicines 
appeared in non-peer-reviewed medical publications.
A total of 191 ‘claims’ could be discerned in 63 unique advertisements 
placed in medical publications, with an average of 3.0 ‘claims’ per 
advertisement. ‘Claims’ were deemed to be statements relating to 
efficacy, safety, tolerability or quality. Examples are statements such as 
“enhancing quality of life” in relation to an advertisement for a hormone 
therapy preparation or “release the crush of osteoporosis”. 
The number of references cited in each advertisement in a medical 
publication ranged from 0 to 12. Only 7/103 (6.8%) references cited 
in unique advertisements in medical publications could be retrieved 
in abstract form from Medline (PubMed). Only 1/7 (14.3%) of these 
references could be retrieved in free full-text format. In total, 14/103 
(13.6%) of the references cited in advertisements placed in medical 
publications were listed as “data on file”. 
The placement of advertisements in close proximity (on either the 
opposite page, same page or overleaf) to an article or advertorial on a 
related subject was identified in 24/63 (38.1%) advertisements.
Compliance with selected elements of the relevant general regulation 
dealing with advertising (General Regulation 45, issued in terms of 
the Medicines and Related Substances Act, No. 101 of 1965) and the 
draft code of practice is shown in Table II. For unique advertisements 
placed in medical publications, high levels of compliance with the 
objective and well-established standards related to inclusion of the 
approved (generic) and proprietary (trade) names, quantitative list of 
active ingredients, scheduling status, registration details and details of 
the licence holder (manufacturer) were shown. Although the number of 
unique advertisements retrieved from consumer publications was low, 
the level of compliance with these requirements (which related more 
directly to the existing General Regulation 45) was far lower. In the case 
of the three advertisements for unregistered complementary medicines, 
compliance with some of these requirements was not possible.
Table I: Source of advertisements over time
Year of publication   2001 2002 2003 2004 2005 Total   
Medical publications (total) 34 12 24 32 34 136   
Medical publications (unique) 14 8 14 13 14 63  
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Elements included in the draft code of practice were more likely to be 
difficult to assess or ambiguous. Only 10/63 (15.9%) unique advertisements 
placed in medical publications included both recommended dosages and 
methods of use. Side effects and special precautions were mentioned in 
7/63 (11.1%) of such advertisements. Compliance with the requirements 
in regard to the placement and size of the proprietary name was seen in 
only 16/63 (25.4%) of such advertisements. 
Judgment of the relevance of the artwork to the indication or of the 
supposed target market to the indication is highly subjective. Although 
low levels of compliance were adjudged, these findings could be 
challenged. Levels of compliance were therefore indicated as “not 
determined”. 
Discussion
Print advertisements remain an important part of the marketing efforts 
of pharmaceutical manufacturers, especially in countries that do not 
provide for legal advertising of prescription medicines to the general 
public. In South Africa, an exception to the general regulation prohibiting 
the advertising of prescription medicines to the public allows the 
advertiser to announce the price of a particular pack size and strength of 
a product. Advertising of the indication for which a prescription medicine 
is registered, without mentioning the name of the medicine, but including 
elements of the “trade dress”, such as a logo or colour associated 
with the product, is not specifically proscribed. Print advertisements 
in publications intended for the professional audience can, however, 
contain far more details, provided they comply with the minimum 
requirements of the general regulations. Such advertisements can be 
considered to be complementary to the efforts of sales representatives 
and industry-associated educational events. The publications in which 
these advertisements appear and the pharmaceutical manufacturers 
have been described as “uneasy bedfellows”, as the journals are heavily 
dependent on advertising for revenue, but can exert little influence over 
the quality of such advertising.6 
The volume of print advertising for pharmaceutical products is immense, 
and this study therefore chose to focus on a single area in which a 
range of products was expected to be advertised. Similar studies have 
focused on different clinical areas, such as antihypertensive medicines, 
lipid-lowering agents and medicines for rheumatology.7,8,9 Each of these 
studies used a cross-sectional design. Although this study set out to 
cover a specific time period, the extensive re-use of the same or similar 
advertisements in different years precluded the use of any time series 
analyses. 
 As only 7/103 (6.8%) references cited in unique advertisements in medical 
publications could be retrieved in abstract form from Medline, the quality 
of these references was not assessed. Greving et al have recently shown 
the references cited in advertisements for antihypertensive agents in a 
Dutch medical journal to be of questionable relevance.7 In 35% of the 
unique advertisements assessed, the claims made were not supported 
by the evidence presented. A cross-sectional analysis of advertisements 
in six ‘popular’ Australian medical publications showed that only 45% of 
the claims made were supported by “compelling evidence” (defined as a 
randomised clinical trial or better).10 A more recent study of advertisements 
in reputable rheumatology journals showed that only 6.4% of the 190 
referenced claims in 84 unique advertisements were “well supported” 
by the literature cited.9 These results were broadly in concert with those 
from older studies, also conducted in North America.11
A particular problem is faced by any reader of advertisements when the 
reference cited is in the form of “data on file”. In this study, 14/103 
(13.6%) of the references cited in advertisements placed in medical 
publications were in this format. Such references cannot be retrieved 
without contacting the manufacturer. Lexchin and Holbrook assessed the 
quality of references cited in advertisements placed in the most widely-
read peer-reviewed Canadian medical journal. Of the 87 references 
requested from advertisers, 10 (11.5%) were listed as “data on file”, 
and only six were supplied. The methodological quality of such studies 
cannot be assessed without access to the original material. In the study 
of advertisements for rheumatology products, 54.6% of those references 
considered to be poor support for the claims made, the source was listed 
as “data on file”.9 An analysis of 438 unique advertisements appearing 
in the 1999 issues of 10 American medical journals (nine of which were 
peer-reviewed) showed that 28% of the 721 references cited were listed 
as “data on file”.12,13
Similar problems have also been detected in other marketing media used 
to bring medicine-related information to the attention of prescribers. 
An analysis of the advertisements included in Australian prescribing 
software showed that compliance with the requirements for included 
information was far from universal.14 Only 11% provided a substantiating 
reference. Printed brochures are another common form of marketing 
aid provided to prescribers. Such brochures may highlight the results 
Table II: Compliance with existing and proposed standards
Quality standard Medical publications   
(n = 63 unique 
advertisements)  
  n %   
Name of medicine (proprietary and approved name) included 57 90.5   
Quantitative list of ingredients (using approved names)   56 88.9   
At least one indication consistent with the approved  
package insert   
49 77.8   
Statement of information relating to dosage and method of 
use, relevant to indications quoted in the advertisement, and 
consistent with the package insert   
10 15.9   
Statement of information relating to side effects, precautions 
and contraindications, relevant to indications quoted in the 
advertisement, and consistent with the package insert
7 11.1   
Scheduling status and pharmacological classification   57 90.5   
Registration number, name and address of registered licence-
holder or part of business responsible for sale and supply   
52 82.5   
Placement of approved name of medicine or list of active 
ingredients (using approved names) immediately adjacent 
(before/after/above/below) to the most prominent display of the 
proprietary name in at least 6-point Helvetica bold   
16 25.4   
Relevance of the artwork (charts/graphs/tables) to the claims 
and comparisons made
nd -   
Artwork presented in a clear (labelled adequately), fair (not 
giving visually misleading impression of the data shown), 
balanced (complete information supplied) manner
nd -   
Logo and trade dress subordinate in size, concentration of 
colours and visual impact to the proprietary (trade) name of the 
medicine   
29 46.0   
Relevance of the illustration to the indication   10 15.9   
Relevance of the target market to the indication   21 33.3  
nd – could not be determined
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of a single study. An American analysis found that 75.0% of 20 such 
brochures contained claims supported by the original study.15 A more 
wide-ranging study, based on 175 different brochures collected from 
45 Pakistani general practitioners’ offices showed that 44.4% of the 
559 references cited were not traceable in PubMed.16 Of those that were 
traceable, 63.5% made “justifiable” claims. Only 1.4% were cited as 
“data on file”.
Citation of “evidence” is not the only way in which a marketing message 
can be conveyed. Ferner has argued that advertisers are “increasingly 
using symbols to circumvent logical argument when trying to persuade 
people … to make choices that are not strictly rational”.17 Graphical 
representations of data or the subtle juxtaposition of advertising and non-
advertising material may serve this purpose. In this study, a considerable 
proportion of advertisements in both medical and consumer publications 
were placed in close proximity to an article or advertorial on a related 
subject. This practice requires the active involvement of both parties. 
While acknowledging that the current business model for most medical 
journals is reliant on advertising revenue, it has been suggested that 
acceptance of such revenue sources “compromise[s] the objectivity of 
journals”.18 
The greatest difficulty was experienced when attempting to apply the 
elements of the draft code of practice that deal with the subtleties of 
image and symbol. Item 5.8 of the draft code states that: “All artwork, 
including illustrations, graphs, tables, logos and trade dress must 
conform to the letter and spirit of the Code. Graphs and tables must 
be presented in such a way as to give a clear, fair, balanced view of the 
matters with which they deal, and must not be included unless they 
are relevant to the claims or comparisons being made”. Graphs are 
commonly utilised in medical brochures that attempt to convey scientific 
evidence. Cardarelli et al showed that 95% of 20 such brochures include 
at least one graph.15 A study specifically addressing this issue showed 
that 36% of 74 graphs in 64 unique advertisements could be considered 
to include numerical distortions.19 Examples included improperly scaled 
or split axes, 3-dimensional elements that improperly compared volume 
instead of other properties such as length, and improper baselines. While 
assessing compliance with the ‘letter’ of a code is somewhat easier, 
compliance with the ‘spirit’ of the code must, of necessity, be highly 
subjective.
A key element of Section 18C of the Medicines Act is the requirement 
that the code of practice be “enforceable”. Reliance on industry self-
regulatory codes has long been criticised.20,21 Shapiro has argued that 
“[o]ur best hope of counteracting the power and influence of the drug 
industry lies in regulation by government agencies, whose interest is the 
protection of the public”.22 Even if such regulation were in force, health 
professionals would still need to be empowered to assess all marketing 
materials critically.23 Although this study was limited in the type of 
advertisements sought, the publications searched and the elements 
assessed, the results obtained mirrored those from a wide variety of 
settings. The need for effective regulation of the quality of pharmaceutical 
advertising, of various types, would seem to be established. Although 
a trend towards more consumer-directed advertisements was shown, 
as well as advertisements for unregistered complementary medicines, 
whether this represents an attempt to escape the more stringent 
control of the envisaged code cannot be stated with any certainty. It 
does, however, point to the need for effective regulation of all forms of 
advertisements and products.
Conclusions
The quality of advertisements for reproductive health products placed in 
medical publications appears to fall short of at least some requirements 
of both existing and draft regulatory instruments. This may potentially 
have deleterious consequences for prescriber behaviour.24 The draft 
code of practice is, however, often difficult to apply in an objective and 
consistent manner, and may be open to interpretation and therefore 
variable standards of quality. 
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QUESTIONNAIRE:
A. GENERAL INFORMATION
1. Month of publication:  January    February    March 
2. Year of publication:     2001     2002     2003     2004     2005
2.1.1. Name of publication:      SAMJ     SAFP     CME
Medical Chronicle     Modern Medicine 
2.2. Which of the following categories does the publication fit: 
2.2.1. Peer reviewed  Yes  No
2.2.2. Not peer reviewed  Yes  No
3.
Is the ad positioned in proximity (opposite 
page, same page, overleaf) to an article or 
advertorial on a related subject or condition:
 Yes  No
4. Does the ad contain a reference:  Yes  No
4.1.1. If yes how many references: 
4.1.2. How many of these references are retrievable from Pubmed: 
B. TECHNICAL CONTENT
1. How many claims have been made in the ad?:
2. How many claims have been referenced?: 
3. What medical condition information is supplied in the ad: 
3.1. Condition name:  Yes  No
3.2. Misconceptions:  Yes  No
3.3. Prevalence:  Yes  No
3.4. Symptoms:  Yes  No
3.5. Typical patient profile:  Yes  No
4. What treatment information is supplied in the ad: 
4.1. Competing treatments:  Yes  No
4.2. Mechanism of action:  Yes  No
4.3. Success rate:  Yes  No
4.4. Supportive behaviours:  Yes  No
4.5. Time to onset of action:  Yes  No
4.6. Treatment duration:  Yes  No
4.7. Class of drug:  Yes  No
4.8. Dosage:  Yes  No
5. Does the ad contain any of the following:
5.1.
Inadequate indications:  Yes  No
(e.g. “Tranquility with simplicity”, “Light up your patients day”)
5.2.
Approved/reliable:  Yes  No
(e.g. “You can trust it. Prescribe it”, “The drug most used by doctors”)
5.3.
Standard or reference medication:  Yes  No
(e.g. “World leader in X”, “first choice”, “WHO reference drug”)
5.4.
Approved by a responsible agency:  Yes  No
(e.g. “Approved by the MCC”)
5.5.
Absence of interactions:  Yes  No
(e.g. “Does not have drug interactions”)
5.6.
The most prescribed one:  Yes  No
(e.g. “The most prescribed antidepressant”)
5.7.
Quick relief:  Yes  No
(e.g. “Rapid onset of action”, “immediate relief”)
5.8.
Suggestion of a wide spectrum:  Yes  No
(e.g. “for all types of anxiety”, “wide solution”)
5.9.
Physiological action:  Yes  No
(e.g. “The right physiological answer”)
5.10.
Certainty of efficacy:  Yes  No
(e.g. “Will work each time, every time”)
5.11.
Pharmacokinetics:  Yes  No
(e.g. “Superior pharmacokinetics for a better life”)
6. How would the advertising slogan be classified? 
6.1.
Claims of efficacy:  Yes  No
(e.g. With improvement of outcomes)
6.2.
Claims of safety:  Yes  No
(e.g. Reduction in adverse effects)
6.3.
Claims of convenience:  Yes  No
(e.g. Ease of administration, improvement of dose)
6.4.
Claims of cost:  Yes  No
(e.g. Low price, better cost effectiveness ratio).
6.5. Claims of prevalence:  Yes  No
6.6. None of the above:  Yes  No
6.7. Unsure:  Yes  No
Complete for each claim made within the advert.
7. How would you classify the claim:
7.1. Unambiguous clinic outcomes:  Yes  No
(e.g. When compared with DRUG X, DRUG Y delivers faster symptom relief.
End points e.g. mortality, infarcts, and readmissions)
7.2. Vague clinical outcomes:  Yes  No
(e.g. DRUG X is the new, effective 20mg pill with a low incidence of 
discontinuation due to skin irritation.
Surrogate end points e.g. decrease in arterial pressure, lipid concentrations)
7.3.
Emotive or immeasurable outcome:  Yes  No
(e.g. DRUG X is one of a kind or DRUG X is a source of healing power)
7.4. Non clinical outcome:  Yes  No
(e.g. Using DRUG X resulted in a 30% increase in arterial luminal diameter in 
post-mortem dissections. I.e. drug plasma t1/2 or biochemical marker.
Pathophysiological endpoints e.g. regression of atheroma plaques, changes in 
arterial diameter.)
7.5. None of the above:  Yes  No
Points 8 - 9 are to be complete for each reference.
8. What is the level of evidence used to support the claim? 
8.1.
Is the claim supported by level 1 evidence:  Yes  No
(i.e. Meta-analysis or systematic review)
8.2.
Is the claim supported by level 2 evidence:  Yes  No
(i.e. Randomized controlled trial)
8.3.
Is the claim supported by level 3 evidence:  Yes  No
(e.g. Other study e.g. cohort)
8.4.
Is the claim supported by level 4 evidence:  Yes  No
(e.g. Expert opinion, data on file, conference proceedings)
9. What are the financial sources of the study being described?
The study is funded by:
9.1. Pharmaceutical industry:  Yes  No
9.2. Nonprofit organization:  Yes  No
9.3. Mixed financing:  Yes  No
9.4. Government:  Yes  No
9.5. Not stated:  Yes  No
9.6. Unsure:  Yes  No
Points 10 - 17 are only to be completed for adverts where references 
corresponded to Level 1 or 2 evidence. Complete for each Level 1 and 2 evidence.
10.
Was the study described as randomized:  Yes  No
(i.e. This includes words such as randomly, random and randomization)
11.
Was the method used to generate the sequence of 
randomization described and appropriate:  Yes  No
(i.e. Table of random numbers, computer generated)
12. Was the study described as double blind:  Yes  No
13.
Was the method of double blinding described 
and appropriate:  Yes  No
(e.g. Identical placebo, active placebo, dummy)
14. Was there a description of withdrawals and drop-outs:  Yes  No
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4. Is a comparison made in the ad:  Yes  No
If yes:
4.1. Are medicines for the same purpose are compared:  Yes  No
4.2. Are one or more area of comparison made:  Yes  No
4.3.
Is there any confusion between the medicine advertised and that of the
competitor with respect to trademark, proprietary
name or other distinguishing feature:  Yes  No
4.4.
Is the trademarks, proprietary name, other distinguishing feature, medicine, 
services, activities or circumstances of a
competitor discredited or denigrated.:  Yes  No
4.5.
Is an unfair advantage being taken of the reputation of a trademark,
proprietary name or other distinguishing marks
of the competitor:  Yes  No
4.6.
Is the medicine being presented as an imitation or replica of the goods
bearing the competitor’s trademark or trade name:  Yes  No
5. Does the ad contain references:  Yes  No
If yes:
5.1. Are clear and complete references provided:  Yes  No
5.2.
Can the information, comparisons and claims be substantiated:
 Yes  No
6.
Is the artwork (illustrations, graphs, tables, logo and trade dress) relevant
to the claims and comparisons being made:  Yes  No
7.
Is the artwork (illustrations, graphs, tables, logo and trade dress) presented in 
a clear (labeled adequately),fair (not giving visually misleading impression as 
to the data shown), balanced manner (complete information supplied) relating 
to the issue that they are
dealing with:  Yes     No     Unsure
8.
Is the logo and trade dress subordinate in size, concentration of colours and
visual impact to the trade name of the medicine:  Yes  No
9.
Is the artwork (illustrations, graphs, tables, logo and trade dress) 
relevant to the indication:  Yes  No
10.
Is it relevant to the target audience relating to 
the indication:  Yes  No
(i.e. Promotes use of the drug in appropriate populations)
11.
Are the words proven safe/ safety or demonstrated safe/ safety 
used without qualification:  Yes  No
12.
Are there claims of no side effects, toxic hazards or risk 
of addiction:  Yes  No
13.
Does the ad contain the words ‘the best’, ‘the strongest’, ‘the 
widest’ etc implying that it is in effect the best:  Yes  No
14.
Does the ad contain the words ‘the’ and ‘unique’ other than to 
define a clearly defined special feature:  Yes  No
15.
Does the ad contain the word ‘new’ unless the product has been
available for less than 12 months on the market:  Yes  No
16.
Does the ad contain a proprietary name of 
another company’s product:  Yes  No
16.1. If yes – has consent been given:  Yes  No
17.
Does the ad disparage the medicines, products and activities 
of other pharmaceutical companies:  Yes  No
18.
Does the ad disparage the scientific and clinical opinion of 
health care professions:  Yes  No
19. Does the ad resemble advertorial matter:  Yes  No
20.
If yes – does it clearly state that it is advertorial or a 
sponsored feature:  Yes  No
     
15.
Was the method used to generate the sequence of randomization was
described and was inappropriate:
(e.g. Patients were allocated alternatively, or 
according to date of birth, hospital number)  Yes  No
16.
Was the study described as double blind but 
the method of blinding was inappropriate:  Yes  No
(e.g. Comparison tablet vs. injection with no double dummy)
17. Quality of the quantitative data quoted:
17.1. Was the p value given:  Yes  No
17.2. Were Confidence Intervals given:  Yes  No
17.3. Was the number needed to treat explicitly stated, if pertinent:  Yes  No
17.4. Power mentioned, if pertinent:  Yes  No
C. COMPLIANCE WITH THE CODE OF MARKETING PRACTICE:
All adverts to be reviewed.
1. Does the following information appear in the ad:
1.1.
Name of the medicine:  Yes  No
(i.e. both proprietary and approved name)
1.2. Quantitative list of the active ingredients using approved name:  Yes  No
1.3. At least one indication consistent with the package insert:  Yes  No
1.4.
Statement of information relating to dosage  
and method of use relevant to the indications 
quoted in the ad and consistent with the
 Yes  No
package insert:
1.5.
Statement of information relating to side effects, precautions and contra
indications relevant to the indications quoted in the ad and
consistent with the package insert:
1.6.
Any warnings issued by the MCC and required
to be included in the ad:  Yes  No
1.7. Scheduling status and pharmacological classification:  Yes  No
1.8.
Registration number and name and address of registered license holder
or name and address of the part of the business responsible
for its sale and supply:  Yes  No
2.
Does the approved name of the medicine or list of active ingredients 
using approved names appear immediately adjacent (before, after, 
above or below) to the most prominent display of the proprietary name 
in bold type of size 6 point Helvetica typeface in black on white or in 
type of such size that the approved name or list of active ingredients 
occupies a total area of no less than that
taken up by the proprietary name:  Yes  No
3. Is all the information, claims or comparisons within the ad:
3.1. Accurate:  Yes     No     Unsure
(e.g. Valid comparisons are made e.g. based on therapeutic equivalent 
dose required for the same indication. Economic evaluations are clinically 
appropriate. Correct and truthful information is given)
3.2.
Balanced:  Yes     No     Unsure
(i.e. Appropriately highlights side effects and contraindications. It must not 
raise unfounded hopes of successful treatment or be misleading with respect 
to safety)
3.3.
Fair:  Yes     No     Unsure
(i.e. Presents a reasonable balance between information relating to efficacy 
and side effects and contraindications.)
3.4. Objective:  Yes     No     Unsure
(i.e. If a medicine is described as better than or stronger than or suchlike it 
must show criteria for comparison. Information is provided in an unbiased 
manner.)
3.5.
Unambiguous:  Yes     No     Unsure
(Clear and unmistakable information is supplied)
3.6. Based on the latest evidence:  Yes     No     Unsure
3.7.
Reflects the evidence:  Yes     No     Unsure
(i.e. Does not misrepresents conclusions of clinical trials)
3.8. Not misleading:  Yes     No     Unsure
(i.e. Not a deceptive use of data. E.g. Data from in-vitro studies, studies in 
humans and animals are relevant to the clinical setting. There is a sound 
statistical basis for information. If no significance is reached it is not 
represented to look at such.)
